Avalo Therapeutics, Inc. 8-K

What Happened

• On March 23, 2026, Avalo Therapeutics, Inc. (AVTX) filed a Form 8-K (Item 2.02) to announce its results of operations and financial condition for the year ended December 31, 2025. The company furnished a press release with those results.

Key Details

• Filing date: March 23, 2026 (Form 8-K, Item 2.02).
• Period covered: year ended December 31, 2025.
• The financial results were distributed via a press release furnished as Exhibit 99.1.
• The filing also includes the company’s Interactive XBRL cover page (Exhibit 104).

Why It Matters

• This filing provides investors the company’s latest annual financial performance and condition, which can include revenue, net income/loss, cash position and other operating metrics (details in the furnished press release).
• Retail investors should review the press release (Exhibit 99.1) and the company’s full SEC filings to see the specific figures and any discussion of trends, guidance, or cash runway that could affect valuation or near-term financing needs.